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Abstract
Aim Lipodystrophy syndromes are rare heterogeneous disorders characterized by deficiency of adipose tissue, usually a 
decrease in leptin levels and, frequently, severe metabolic abnormalities including diabetes mellitus and dyslipidemia.
Purpose To describe the clinical presentation of known types of lipodystrophy, and suggest specific steps to recognize, 
diagnose and treat lipodystrophy in the clinical setting.
Methods Based on literature and in our own experience, we propose a stepwise approach for diagnosis of the different 
subtypes of rare lipodystrophy syndromes, describing its more frequent co-morbidities and establishing the therapeutical 
approach.
Results Lipodystrophy is classified as genetic or acquired and by the distribution of fat loss, which can be generalized or par-
tial. Genes associated with many congenital forms of lipodystrophy have been identified that may assist in diagnosis. Because 
of its rarity and heterogeneity, lipodystrophy may frequently be unrecognized or misdiagnosed, which is concerning because 
it is progressive and its complications are potentially life threatening. A basic diagnostic algorithm is proposed. Effective 
management of lipodystrophy includes lifestyle changes and aggressive, evidence-based treatment of comorbidities. Leptin 
replacement therapy (metreleptin) has been found to improve metabolic parameters in many patients with lipodystrophy. 
Metreleptin is approved in the United States as replacement therapy to treat the complications of leptin deficiency in patients 
with congenital or acquired generalized lipodystrophy and has been submitted for approval in Europe.
Conclusions Here, we describe the clinical presentation of known types of lipodystrophy, present an algorithm for differ-
ential diagnosis of lipodystrophy, and suggest specific steps to recognize and diagnose lipodystrophy in the clinical setting.
Keywords Diabetes · Dyslipidemia · Insulin resistance · Leptin replacement · Metreleptin
Introduction
Rare diseases are complex, chronic, often little-known 
conditions that can have debilitating health consequences 
and high morbidity and can impair quality of life. They are 
poorly understood by general practitioners and medical spe-
cialists alike, in part because of their low prevalence and 
frequent phenotypic heterogeneity. Lack of knowledge about 
rare disorders often leads to long delays in diagnosis and 
sometimes to misdiagnosis, which can be greatly detrimental 
to patients.
Lipodystrophy syndromes, a collection of rare hetero-
geneous disorders characterized by a deficiency of adi-
pose tissue without evidence of nutrition deprivation or a 
catabolic state, are no exception [1]. These disorders may 
be associated with a severe form of metabolic syndrome 
caused by abnormal deposition of fat that cannot be stored 
in appropriate subcutaneous depots [2]. Loss of adipose 
tissue frequently results in a decrease in leptin levels [3], 
which interferes with hunger-satiety signals and often leads 
to hyperphagia [4]. Surplus calories are stored as fat in liver 
and muscle tissue, resulting in insulin resistance, hypertri-
glyceridemia, and hepatic steatosis.
Excluding HIV-related lipodystrophy, the worldwide 
prevalence of lipodystrophy was recently estimated from 
searches of large electronic medical record databases to 
be 3.07 cases per million population [0.23 cases/million of 
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generalized lipodystrophy (GLD) and 2.84 cases/million of 
partial lipodystrophy (PLD)]. Through literature searches, 
the prevalence of GLD and PLD was estimated to be 0.96 
and 1.67 cases per million population, respectively [5].
The objective of this review was to establish a phased 
strategy allowing clinicians to attain a reasonably reliable 
diagnosis of the different lipodystrophy subtypes as well as 
to outline the therapeutic approach.
Recognition and diagnosis of lipodystrophy
Recognition of a lipodystrophy disorder is based on clini-
cal history and physical examination that reveal a distinct 
body composition and metabolic state. Lipodystrophy is 
classified according to the manner of acquisition (genetic 
or acquired) and the distribution of adipose deficiency 
(generalized or partial). Thus, there are four major sub-
types: congenital GLD (CGL), acquired GLD (AGL), 
familial PLD (FPLD), and acquired PLD (APL) (Table 1) 
[1].
Because of their rarity and heterogeneity, lipodystro-
phy disorders may frequently be unrecognized or misdi-
agnosed. Clinicians can differentiate lipodystrophy from 
other diseases and determine the appropriate subtype using 
the following steps.
Step 1: Determination of whether the patient 
has lipodystrophy
Because of its pervasive features, GLD represents a 
recognizable phenotype of lipodystrophy. Conversely, 
the presentation of PLD can be more subtle. PLD may 
be recognized, in part, by a characteristic pattern of fat 
loss, described in more detail later in this review [4, 6, 7]. 
Patients with lipodystrophy may present with the disease 
in childhood or as adults, and the onset may be sudden or 
insidious. With few exceptions [8], a major characteristic 
of lipodystrophy disorders is that fat loss never recovers.
Lipodystrophy should be suspected when a patient 
presents with a congenital deficiency of subcutaneous 
adipose tissue (SAT), progressive loss of SAT associated 
with autoimmune diseases, loss of SAT in limbs concur-
rent with the accumulation of fat in other body regions, or 
deficiency of SAT associated with other somatic abnor-
malities [9]. Additional physical features may include fail-
ure to thrive (in children), prominent muscles and veins, 
acanthosis nigricans, eruptive xanthomas, or cushingoid or 
acromegaloid appearance [1]. If the patient also has diabe-
tes mellitus requiring high insulin doses, severe hypertri-
glyceridemia, nonalcoholic steatohepatitis, or polycystic 
ovarian syndrome (PCOS), lipodystrophy may be further 
indicated [9].
Diagnosis of lipodystrophy is based on clinical history, 
physical examination, and assessment of body composi-
tion, with laboratory findings useful in some cases. While 
no firm diagnostic criteria for lipodystrophy have been 
established based on skinfold measurements or imaging 
procedures such as dual-energy X-ray absorptiometry and 
magnetic resonance imaging, all of these evaluations can 
assist with diagnosis [6, 10–13]. Although serum leptin 
levels in patients with lipodystrophy tend to be low (in 
absolute levels or relative to body mass index), no defined 
serum leptin level threshold can be used to rule out the 
diagnosis of lipodystrophy [1].
An algorithm for differential diagnosis of lipodystro-
phy subtypes is shown in Fig. 1. The differential diagnosis 
includes a range of disparate conditions [9, 14, 15] such as 
the following:
• Severe weight loss due to anorexia nervosa, starvation, 
malnutrition, uncontrolled diabetes, hyperthyroidism, 
adrenal insufficiency, cancer cachexia, or severe chronic 
infection.
• Donohue syndrome (leprechaunism) and Rabson–
Mendenhall syndrome, which are both recessive syn-
dromes associated to variants in the INSR gene. Lepre-
chaunism is the most severe disorder characterized by 
craniofacial abnormalities including elfin face, large, 
low-set ears, growth retardation, marked lack of adi-
pose tissue, decreased muscle mass, hypertrichosis, 
pachyderma, acanthosis nigricans, virilization, and 
severe insulin resistance with paradoxical hypoglyce-
mia. Death often occurs during early infancy. Children 
with Rabson–Mendenhall syndrome have a longer sur-
vival (15–20 years old) and present with coarse face 
with prognathism, dental crowding, short stature, thin 
non-lipoatrophic body type, severe acanthosis nigricans, 
phallic enlargement or clitoromegaly, paradoxical hypo-
glycemia, hyperinsulinemia, and diabetic ketoacidosis 
[16].
• Multiple symmetric lipomatosis.
• Cushing syndrome.
Step 2: Evaluation of the extent of lipodystrophy
Once the diagnosis of lipodystrophy is established, clini-
cians should investigate whether the disorder is generalized, 
partial, or localized. In generalized forms, total or near-total 
loss of subcutaneous fat can be observed over the entire 
body. In partial forms, fat loss affects large areas, particu-
larly the limbs, but adipose tissue may accumulate in spared 
regions such as the face and neck in FPLD, while APL is 
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Table 1  Classification of lipodystrophies [1, 17, 25–32, 49–58]
From: Online Mendelian Inheritance in Man (http://www.omim.org)
ALDD autoinflammation, lipodystrophy, and dermatosis syndrome, CANDLE chronic atypical neutrophilic dermatosis with lipodystrophy and 
elevated temperature, JMP joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy, MDPL mandibular 
hypoplasia, deafness, and progeroid features and lipodystrophy, OMIM Online Mendelian Inheritance in Man, SHORT short stature, hyperexten-
sibility of joints, hernia, ocular depression, Rieger anomaly, and teething delay
1 Congenital
 1.1 Generalized (Berardinelli-Seip syndrome)
  1.1.1 Type 1 congenital generalized lipodystrophy (AGPAT2, recessive, OMIM #608594)
  1.1.2 Type 2 congenital generalized lipodystrophy (BSCL2, recessive, OMIM #269700)
  1.2.3 Type 3 congenital generalized lipodystrophy (CAV1, recessive, OMIM #612526)
  1.2.4 Type 4 congenital generalized lipodystrophy (PTRF, recessive, OMIM #613327)
  1.2.5 PPARG -associated congenital generalized lipodystrophy (recessive)
 1.2 Partial
  1.2.1 Type 1 familial partial lipodystrophy (Köbberling syndrome; unknown genes, dominant or polygenic, OMIM #608600)
  1.2.2 Type 2 familial partial lipodystrophy (Dunnigan disease; LMNA, dominant or codominant, OMIM #151660)
  1.2.3 Type 3 familial partial lipodystrophy (PPARG , dominant, OMIM #604367)
  1.2.4 Type 4 familial partial lipodystrophy (PLIN1, dominant, OMIM #613877)
  1.2.5 Type 5 familial partial lipodystrophy (CIDEC, recessive, OMIM #615238)
  1.2.6 Type 6 familial partial lipodystrophy (LIPE, recessive, OMIM #615980)
  1.2.7 AKT2-linked lipodystrophy (dominant)




   1.3.1.1 Hutchinson-Gilford progeria syndrome (LMNA, dominant, OMIM #176670)
   1.3.1.2 Atypical Werner syndrome and atypical progeroid syndrome (LMNA, dominant)
   1.3.1.3 SHORT syndrome (PIK3R1, dominant, OMOM #269880)
   1.3.1.4 MDPL syndrome (generalized or partial; POLD1, dominant, OMIM #615381)
   1.3.1.5 Keppen-Lubinsky syndrome (KCNJ6, dominant, OMIM #614098)
   1.3.1.6 Néstor-Guillermo progeria syndrome (BANF1, recessive, OMIM #614008)
   1.3.1.7 Type B mandibuloacral dysplasia (ZMPSTE24, recessive, OMIM #608612)
   1.3.1.8 Ruijs-Aalfs syndrome (SPRTN, recessive, OMIM #616200)
   1.3.1.9 Cockayne syndrome (ERCC6, ERCC8, recessive, OMIM #133540, #216400)
   Partial
   1.3.1.10 Marfan syndrome with neonatal progeroid syndrome–like lipodystrophy (FBN1, dominant, OMIM #616914)
   1.3.1.11 CAV1-associated neonatal onset lipodystrophy syndrome (dominant)
   1.3.1.12 Werner syndrome (WRN/RECQL2, recessive, OMIM #277700)
   1.3.1.13 Type A mandibuloacral dysplasia (LMNA, recessive, OMIM #248370)
   1.3.1.14 PCYT1A lipodystrophy (recessive)
   1.3.1.15 Bloom syndrome (RECQL3, recessive, OMIM #210900)
   1.3.1.16 Neonatal progeroid syndrome (possibly associated with POLR3A, recessive, OMIM #264090)
  1.3.2 Autoinflammatory syndromes, ALDD (generalized or partial), OMIM #256040
  1.3.2.1 Nakajo-Nishimura syndrome (PSMB8)
   1.3.2.2 JMP syndrome (PSMB8)
   1.3.2.3 CANDLE syndrome (PSMB8)
2 Acquired
 2.1 Generalized
  2.1.1 Acquired generalized lipodystrophy (Lawrence syndrome)
  2.2 Partial
   2.2.1 HIV-associated lipodystrophy
   2.2.2 Acquired partial lipodystrophy (Barraquer-Simons syndrome, OMIM #608709)
   2.2.3 Lipodystrophy associated with total body irradiation and hematopoietic stem cell transplant
 2.3 Localized
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characterized with an opposite distribution of fat. Localized 
forms of lipodystrophy are limited to small body areas.
After determining whether the lipodystrophy is general-
ized or partial, a further specification of the particular type 
of GLD or PLD can be undertaken. Numerous subtypes of 
GLD and PLD have been described, many associated with 
known genetic abnormalities (Table 1).
Step 3.1: Evaluation of GLD
CGL
GLD disorders of genetic origin include Berardinelli-Seip 
syndrome (usually referred to as CGL) and certain disorders 
of premature aging (progeroid syndromes). A key but non-
pathognomonic characteristic to establish the presence of 
CGL is the age at onset of fat loss, which usually manifests 
at birth or during the first year of life. However, in some 
Fig. 1  A guide to diagnosing different subtypes of lipodystrophy. 
Diagnosis of lipodystrophy is largely based on physical examination 
and clinical history. When abnormal fat loss is observed, other dis-
eases (a) causing a negative energy balance should first be excluded 
(malnutrition, anorexia nervosa, uncontrolled diabetes mellitus, thy-
rotoxicosis, adrenocortical insufficiency, cancer cachexia, and chronic 
infections). Recovery of adipose tissue also makes lipodystrophy 
unlikely. Patients with HIV receiving antiretroviral treatment often 
develop a syndrome characterized by peripheral lipoatrophy, trunk 
fat accumulation, and metabolic abnormalities, the pathogenesis of 
which remains not completely defined. Progeroid syndromes may be 
associated with lipodystrophy: Aging traits (b), such as short stature, 
alopecia, graying, sclerodermatous skin changes, skin atrophy, osteo-
porosis, acro-osteolysis, joint contractures, small mandible, dental 
crowding, low muscle mass, joint stiffness, or mottled pigmentation 
of the skin, are highly suggestive of early aging syndromes. Of note, 
fat loss in the face of children may confer an aging appearance that 
should not be considered a progeroid trait. Once the above-reported 
conditions are excluded, the extent of fat loss and the distribution 
of residual adipose tissue must be defined. Localized lipoatrophy 
may develop due to subcutaneous injection of certain drugs or as a 
result of regional panniculitis, in the absence of systemic manifesta-
tions. Extensive thinning of the subcutaneous adipose tissue should 
orientate towards a generalized form, whereas incomplete depletion 
of the adipose pad associated with fat accumulation in the spared 
regions indicates partial lipodystrophy. Both in generalized and par-
tial lipodystrophies, occurrence of affected relatives or parental con-
sanguinity indicates an inherited subtype of the disease, which should 
be confirmed by genetic testing. Fat loss in the lower body with fat 
accumulation in the face and neck is suggestive of FPLD, whereas 
lipoatrophy of the face that progresses to the shoulder girdle, upper 
extremities, and trunk is a sign of APL. Coexisting autoimmune dis-
eases, panniculitis, or inflammatory manifestations (c: see text) at 
various sites advocate the diagnosis of acquired lipodystrophy that 
can be partial at early stages and then evolve as a generalized form. A 
history of total body irradiation, chemotherapy, and allogeneic bone 
marrow transplant in the context of leukemia treatment in childhood 
points to a specific subtype resembling FPLD. AGL acquired general-
ized lipodystrophy, APL acquired partial lipodystrophy, CGL congen-
ital generalized lipodystrophy, FPLD familial partial lipodystrophy
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Fig. 2  Physical appearance of patients with different lipodystrophy 
subtypes. a Congenital subtypes. Congenital generalized lipodystro-
phy (CGL): anterior view of a 15-year-old Caucasian man with type 
2 CGL due to homozygous c.517dupA (p.Thr173AsnfsTer5) in the 
BSCL2 gene; familial partial lipodystrophy (FPLD): anterior view of 
a 27-year-old Caucasian woman with type 2 FPLD due to heterozy-
gous c.1444C>T (p.Arg482Trp) in the LMNA gene; Hutchinson-Gil-
ford progeria syndrome (HGPS): lateral view of a 16-year-old Cau-
casian woman with HGPS due to de novo heterozygous c.1824C>T 
(p.[=, Val607_Gln656del]) in the LMNA gene; Werner syndrome: 
anterior view of a 39-year-old Caucasian man with Werner syn-
drome due to compound heterozygous c.[2886dup]; [1982-5del] 
(p.[Ile965*]; [Tyr660Ilefs7*]) in the RECQL2 gene; atypical progeria 
syndrome (PS): anterior view of a 17-year-old Caucasian man with 
atypical progeroid syndrome due to de novo heterozygous c.29C > T 
(p.Thr10Ile) in the LMNA gene. b Acquired subtypes. Acquired gen-
eralized lipodystrophy (AGL): posterior view of a 35-year-old Cauca-
sian woman with AGL; bone marrow transplant-associated lipodys-
trophy: anterior view of a 23-year-old Caucasian woman with partial 
lipodystrophy associated with bone marrow transplant and total body 
irradiation during childhood as a treatment for acute leukemia; 
acquired partial lipodystrophy (APL): anterior view of a 9-year-old 
Caucasian woman with APL
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CGL subtypes and progeria syndromes, lipodystrophy arises 
during childhood.
CGL is a rare autosomal recessive disorder associated 
with a near total absence of adipose tissue (Fig. 2a) [1, 10]. 
Patients have marked muscularity, apparent phlebomegaly, 
and acanthosis nigricans with acrochordons, which fre-
quently extend beyond the axillae and neck and affect the 
groin, elbow flexion, and abdomen [1, 17]. Patients may 
exhibit acromegaloid features, beginning in adolescence. 
Abdominal distension due to hepatomegaly is usually seen 
from early childhood; hernia or umbilical protrusion is com-
mon [1, 9]. In some cases, hypertrichosis is a prominent 
feature [9]. A voracious appetite is common in early child-
hood [4].
From the first months of disease, patients with CGL may 
present with hypertriglyceridemia that, if severe, can lead to 
acute pancreatitis [9]. Plasma insulin levels are elevated, and 
nonketotic diabetes, usually appearing in the second decade 
of life, is often very difficult to control, even with high doses 
of insulin [9]. Without treatment, the prognosis for patients 
with CGL is poor because of hepatic cirrhosis, cardiovas-
cular complications of diabetes, pancreatitis, or end-stage 
renal disease [9].
The mean leptin level in patients with CGL is 1.0 ng/mL 
and is low regardless of sex and age [18].
In some cases, family history, and almost always pheno-
typic traits, of patients will help in diagnosis of CGL. Con-
sanguinity should be assessed, because the presence of blood 
ties in the parents of the propositus would indicate CGL, and 
the presence of ≥ 1 affected sibling would be almost con-
firmatory, when associated with phenotypic traits.
Certain clinical features may be associated with the gene 
responsible for each subtype of Berardinelli-Seip syndrome 
[1, 9] (Table 1), but genetic testing is required to confirm 
the type of CGL [1]. Types 1 (AGPAT2-associated) and 2 
(BSCL2-associated) CGL are the most frequent, with type 2 
having the most severe metabolic complications and an asso-
ciation with mental retardation [9, 10]. In particular, some 
variants in BSCL2 are associated with lethal encephalopathy 
in early childhood [19]. Patients with CGL and BSCL2 vari-
ants have lower leptin levels and an earlier onset of diabetes 
than those without these variants [10]. Hypertrophic car-
diomyopathy has been reported in types 1 and 2 CGL, as 
well as accelerated growth and, in women, clitoromegaly 
and precocious puberty [9, 20]. Conversely, mechanical fat 
(e.g., palms and soles) is reduced in type 2 CGL, while it is 
conserved in other types [9, 21].
Additional clinical features such as muscle mounding, 
muscle weakness, atlantoaxial instability, cardiac arrhyth-
mias, osteopenia, distal metaphyseal deformation with joint 
stiffness, hypertrophic pyloric stenosis, and esophageal dys-
motility can be highly suggestive of type 4 Berardinelli-Seip 
syndrome [22, 23], associated to variants in the PTRF gene.
In early childhood, Berardinelli-Seip syndrome may be 
confused with Rabson–Mendenhall syndrome and some-
times with Donohue syndrome (leprechaunism). Severe 
acanthosis nigricans and clitoromegaly can be confound-
ing factors in the diagnosis. However, facial features in 
those with Rabson–Mendenhall syndrome are distinct and 
loss of fat, if any, is hardly evident. During adolescence or 
adulthood, some patients with Berardinelli-Seip syndrome 
have marked acromegaloid features. Absence of gigantism, 
generalized loss of subcutaneous fat, apparent hypermus-
culation, and severe insulin resistance make the differential 
diagnosis with acromegaly straightforward. If elements of 
doubt should persist, a normal suppression of serum growth 
hormone following administration of oral glucose is enough 
to exclude this disorder [24].
Progeroid syndromes
Contrasting with the genetically recessive nature of Berar-
dinelli-Seip syndrome, progeroid syndromes associated 
with GLD may be dominant (usually de novo) or recessive 
[25–32] (Table 1). Some features, such as short stature, 
alopecia, graying, sclerodermatous skin changes, skin atro-
phy, osteoporosis, acro-osteolysis, joint contractures, small 
mandible, dental crowding, low muscle mass, joint stiffness, 
or mottled pigmentation of skin, among others, are highly 
suggestive of early aging syndromes [33]. For a description 
of subtypes, see specific references [25–32, 34] (Fig. 2a).
AGL
Compared with CGL, AGL (Lawrence syndrome) has a later 
onset (childhood or adolescence) and is more common in 
women than men (3:1 ratio) (Fig. 2b) [11]. The loss of adi-
pose tissue occurring in childhood or adolescence, preceded 
or followed by autoimmune manifestations at various sites, 
may suggest a diagnosis of AGL [1]. Initially, subcutaneous 
fat loss may occur at limited locations, but it tends to gen-
eralize with progression of the disease over weeks, months, 
or years. Sometimes, facial fat loss is not initially present, 
although it usually occurs over time. In some cases, AGL is 
a phenocopy of Berardinelli-Seip syndrome.
Insulin-resistant diabetes, severe hypertriglyceridemia, 
hepatic steatosis, and insulin-resistance stigmata are frequent 
comorbidities of AGL. Hyperinsulinemia and low plasma 
leptin levels are typically present. Loss of fat in the palms 
and soles has been reported in approximately one-third and 
one-half of patients, respectively [11]. There is no family 
history of lipodystrophy in cases of AGL, but the presence 
of other autoimmune diseases in relatives may assist in the 
diagnosis. Activation of the classical complement pathway 
and low C4 complement levels have been associated with 
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low leptin and adiponectin levels and with destruction of 
adipocytes and lipodystrophy in patients with AGL [35].
Three subtypes of AGL (panniculitis, autoimmune, and 
idiopathic) have been proposed [11]. Lipodystrophy onset 
has been associated with the appearance of panniculitis 
in ~ 25% of cases and autoimmune disease in another 25% 
of cases, but no specific causes could be identified in most 
cases (idiopathic). Patients who developed AGL in associa-
tion with autoimmune disease tended to be older than those 
with other AGL subtypes [11]. In particular, the autoimmune 
disease juvenile dermatomyositis has been associated with 
AGL [36]. Based on an analysis of a case series, disease 
associated with panniculitis may progress more slowly than 
either autoimmune or idiopathic AGL, with a lower preva-
lence of diabetes and hypertriglyceridemia [11].
Step 3.2: Evaluation of PLD
The distribution of fat loss, age of onset, certain phenotypic 
traits, and family history are determining factors in diag-
nosing the subtypes of PLD, which include congenital and 
acquired disorders (Table 1).
PLD of genetic origin
PLD disorders of genetic origin are described further in the 
following sections and include FPLD, certain progeroid syn-
dromes, and autoinflammatory syndromes. Many forms of 
PLD are associated with known genetic abnormalities, and 
genetic tests are needed to confirm the presence of currently 
identified mutations in some PLD subtypes [1].
FPLD FPLD encompasses a number of conditions sharing 
a Cushingoid appearance and a variable association with 
excess body weight (Fig. 2a). The loss of subcutaneous fat 
in the limbs and gluteal region, observed around childhood 
or puberty and associated with accumulation of excess fat 
in the face, neck, and intra-abdominal region, is suggestive 
of FPLD [9].
Eight subtypes of FPLD have been reported [17] 
(Table 1). Type 1 FPLD (Köbberling syndrome) is an early-
onset, inherited variety of PLD, although no specific genes 
are known to be involved, and a dominant or polygenic 
pathogenesis has been suggested [12, 37, 38]. The diagno-
sis of type 1 FPLD is challenging because it can be easily 
confused with android obesity in women associated with 
metabolic syndrome. Patients with type 1 FPLD are usually 
obese and have a significant accumulation of abdominal fat, 
with lipoatrophy most evident in the hips and lower extrem-
ities [12]. The disease may represent part of a spectrum 
encompassing essential central obesity, and specific cutoffs 
for thickness and distribution of SAT that can be useful for 
clinical purposes have been proposed [12].
The classic phenotype of FPLD (type 2, Dunnigan dis-
ease) is currently attributed to variants in exon 8 of the 
LMNA gene. Fat loss begins around puberty in women 
and often goes unnoticed in men because of the particular 
distribution of body fat. Affected men are often diagnosed 
when an affected female relative is identified. Fat loss is 
present in the limbs, trunk, hips, and buttocks. Strikingly, 
these patients have accumulation of fat in the face, neck, 
axillae, interscapular region, abdominal visceral area, and 
labia majora [39]. The musculature is well defined and may 
even include muscular hypertrophy in the calves, as well as 
apparent phlebomegaly.
Patients with type 2 FPLD, especially women, frequently 
present with early insulin resistance that may lead to dia-
betes, hypertriglyceridemia (sometimes severe and causing 
acute pancreatitis), low high-density lipoprotein cholesterol, 
hepatic steatosis, and an increased risk of cardiovascular dis-
ease; sometimes these patients also present with acanthosis 
nigricans (although not as severe as in GLD). PCOS is not 
uncommon, as well as obstetric problems (i.e., gestational 
diabetes, miscarriage, and stillbirth), muscle aches, and lipo-
mas [39, 40].
Family history (dominant vs. recessive) and certain phe-
notypic traits and associated disorders may guide molecu-
lar diagnosis. For example, in type 2 FPLD there may be 
valvular heart disease, myocardial hypertrophy, and/or 
cardiac conduction system disorders. Other laminopathies 
(Emery-Dreifuss muscular dystrophy, limb-girdle muscular 
dystrophy, or familial dilated cardiomyopathy) may also be 
associated with type 2 FPLD or even be present in other 
family members [41]. Thus, a careful cardiac evaluation is 
encouraged. Mutations in exons other than exon 8 in LMNA 
can lead to atypical forms of type 2 FPLD, in which lipod-
ystrophy is less evident, or can even be confused with Köb-
berling syndrome.
In type 3 FPLD, lipoatrophy appears in adulthood, with 
no fat accumulation in the face or neck. Cardiometabolic 
complications are usually severe [42]. In type 4 FPLD, 
lipoatrophy appears in childhood or in adulthood, with pos-
sible accumulation of facial fat. These patients also exhibit 
severe dyslipidemia and insulin-resistant diabetes [43].
Types 5 and 6 FPLD are recessive conditions, and only a 
few cases have been reported [44–46]. Type 5 FPLD appears 
in early childhood, while type 6 appears in adulthood. In 
type 5 FPLD, there is muscular hypertrophy but no accu-
mulation of adipose tissue. Accumulation of fat in the neck, 
axillae, back, and supraclavicular area; muscular dystrophy 
(weakness); elevation of creatine kinase; and hypertriglyc-
eridemia have been reported in type 6 FPLD. Because of 
this particular fat distribution, FPLD must be differentiated 
from Cushing syndrome. Chronic hypercortisolism causes 
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a characteristic centripetal fat distribution [47], but no par-
ticular changes in limb fat have been reported, and muscle 
wasting is evident [48].
Progeroid syndromes Progeroid syndromes associated with 
PLD are shown in Table 1 (Fig. 2a) [49–55]. All of these 
syndromes have particular clinical features of early aging, 
the detailed description of which is beyond the scope of this 
review.
Autoinflammatory syndromes Autoinflammatory syn-
dromes causing lipodystrophy include Nakajo-Nishimura 
syndrome; joint contractures, muscle atrophy, microcytic 
anemia, and panniculitis-induced lipodystrophy (JMP) 
syndrome; and chronic atypical neutrophilic dermatosis 
with lipodystrophy and elevated temperature (CANDLE) 
syndrome. These disorders begin in childhood, and the 
lipodystrophy can be generalized or partial, affecting the 
face and limbs. All are recessive disorders related to muta-
tions in genes encoding for proteins that are essential for 
the maturation and assembly of the proteasome subunits 
[56–58]. Normally, type 1 interferon secreted by cells after 
viral infection or other triggers activates the JAK/STAT 
pathway that produces reactive oxygen and nitrogen species 
with defensive function. These oxidant molecules may be 
detrimental to functional integrity of cell proteins and are 
usually removed by the proteasome–immunoproteasome 
system. In autoinflammatory syndromes, cells with mutated 
proteasome–immunoproteasome will not be able to remove 
all waste proteins. As a result, an abnormal cellular stress 
occurs, leading to additional type 1 interferon production 
and perpetuation of tissue damage [59].
Nakajo-Nishimura syndrome is an inflammatory disease 
involving lipomuscular atrophy and joint contractures [57]. 
As indicated by its name, JMP syndrome is characterized 
by joint contractures, muscular atrophy, microcytic anemia, 
and panniculitis-induced lipodystrophy [60]. Other charac-
teristics include intermittent fever, hypergammaglobuline-
mia, increased sedimentation rate, hepatosplenomegaly, and 
calcification of the basal ganglia. In CANDLE syndrome, 
patients present with childhood-onset recurrent fevers and 
violaceous annular plaques on the eyelids and lips, evolving 
through childhood to a loss of subcutaneous fat in the face 
and upper limbs. Patients also have hepatosplenomegaly, 
arthralgias, microcytic anemia, increased sedimentation rate, 
and calcifications in the basal ganglia [61].
APL
APL includes HIV-associated lipodystrophy, Barraquer-
Simons syndrome, and bone marrow transplant–associ-
ated lipodystrophy. While lipodystrophy in patients with 
HIV receiving long-term antiretroviral therapy is the most 
common form of lipodystrophy [62], it is out of the scope 
of this review.
Barraquer‑Simons syndrome Barraquer-Simons syndrome 
is a very rare disorder of unknown etiology (possibly auto-
immune) characterized by a cephalocaudal loss of SAT. It 
is more common in women than men (4:1 ratio) (Fig. 2b), 
and fat loss usually begins in late childhood or adolescence. 
Fat loss initially affects the head, giving children an aged 
appearance, and progresses to the shoulder girdle, upper 
extremities, and trunk [1] in a process that can last weeks, 
months, or years. When affected women gain weight, they 
accumulate fat in the lower extremities, presenting a unique 
phenotype of APL. The arms have well-defined musculature 
and apparent phlebomegaly. Acanthosis nigricans is gener-
ally absent [6]. Although the etiology of APL is unknown, 
the presence of other autoimmune diseases may help con-
firm the diagnosis, in particular membranoproliferative glo-
merulonephritis, which can lead to kidney failure [1].
Although reports of metabolic complications have gener-
ally been uncommon in Barraquer-Simons syndrome [6], a 
recent study suggests that these complications have been 
underestimated [63]. Patients tend to have low serum C3 
complement and leptin levels and detectable C3 nephritic 
factor [6].
Bone marrow transplant‑associated lipodystro‑
phy Recently, lipodystrophy following total body irradia-
tion, chemotherapy, and allogeneic bone marrow transplant 
has been reported as a phenocopy of FPLD [64–66]. This 
form of APL affects patients who underwent bone marrow 
transplant in the context of leukemia treatment in childhood 
(Fig. 2b).
Localized lipodystrophy disorders
Localized lipodystrophy disorders involve small amounts of 
fat loss due to drugs, panniculitis, or unknown etiology [17]. 
The amount of fat loss is minimal; therefore, these disorders 
are not associated with metabolic abnormalities.
Complications of lipodystrophy
Deficient adipose mass in lipodystrophy results in a collec-
tion of typical metabolic complications that include insulin 
resistance and diabetes, hypertriglyceridemia, PCOS, and 
nonalcoholic fatty liver disease [1]. In patients with lipodys-
trophy, these complications are sequelae of the defects that 
led to altered adiposity [1]. Causes of premature mortality 
include cardiovascular disease, liver disease, kidney failure, 
pancreatitis, and sepsis [1, 11, 67, 68].
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Treatment approach for lipodystrophy
Lipodystrophy is a progressive and life-threatening disease. 
Currently, there is no cure for lipodystrophy. Metabolic 
comorbidities must be treated to manage the short- and long-
term complications of the disease.
Treatment of comorbidities
Diet and exercise are important factors in managing lipo-
dystrophy comorbidities. Practice guidelines recommend 
that patients adhere to a balanced diet, including ~ 50 to 60% 
carbohydrates, 20–30% fat, and 20% protein. Because hypo-
leptinemia (absolute or relative) stimulates appetite and food 
consumption, energy restriction is usually recommended to 
reduce ectopic fat storage and improve metabolic abnormali-
ties, although it may be difficult to achieve, especially in 
childhood and adolescence. Of note, growth assessment may 
be challenging because of the abnormal body composition 
and the underlying primary disease that may affect linear 
growth independent of lipodystrophy. Very low–fat diets 
should be used in patients with acute pancreatitis. Physical 
exercise should be advised, if not contraindicated by con-
current diseases, but limitations may intervene because of 
musculoskeletal pain, fatigue, or psychological distress [1]. 
Plastic surgery (breast implants, dermal fillers, lipectomy, 
or liposuction) and psychological support can improve the 
well-being of some patients.
In addition to lifestyle changes, patients with lipodystro-
phy should receive medical treatment for specific metabolic 
comorbidities. Clinicians should follow national or inter-
national guidelines in the diagnosis and management of 
diabetes, dyslipidemia, hypertension, and renal and hepatic 
disease. As discussed in the next section, leptin replacement 
therapy may reduce the need for treatment of metabolic 
comorbidities.
Leptin replacement therapy
Metreleptin  (Myalept®, Aegerion Pharmaceuticals, Cam-
bridge, MA, USA) is the only drug indicated specifically 
for the treatment of lipodystrophy, although many therapies 
are used to treat comorbid conditions. Metreleptin is a leptin 
analogue indicated in the United States as an adjunct to diet 
as replacement therapy to treat the complications of leptin 
deficiency in patients with CGL or AGL [69]. Metreleptin 
has been submitted to the European Medicines Agency for 
approval in the treatment of patients with CGL, AGL, and 
certain types of PLD.
Metreleptin for GLD
Patients receiving metreleptin typically report an immedi-
ate decrease in appetite and reduction in food intake [70]. 
Metreleptin treatment has been associated with an improved 
metabolic profile in patients with GLD [71]. An open-label 
cohort study conducted at the National Institutes of Health 
(NIH) reported reductions in hemoglobin A1c (HbA1c), 
fasting plasma glucose, and triglycerides within 4 months 
of initiating treatment, which were maintained for ≥ 3 years 
in patients with CGL or AGL and at least 1 of 3 metabolic 
abnormalities (diabetes, insulin resistance, and/or hypertri-
glyceridemia) [71, 72]. Patients receiving metreleptin were 
often able to eliminate or greatly reduce the dosage of their 
antidiabetes medications [73]. The long-term improvements 
in metabolic parameters continued to accrue even after 
reduction or discontinuation of antidiabetic therapy [73, 74].
Leptin replacement therapy is also associated with 
decreased liver volume and serum aminotransferase levels 
[71, 73, 74]. Paired biopsy studies have shown that nonalco-
holic steatohepatitis associated with GLD was ameliorated 
with metreleptin treatment [75, 76]. During 52 weeks of 
metreleptin treatment, improved brain connectivity associ-
ated with hedonic and homeostatic control of eating behav-
ior, decreased hunger, and increased satiety were observed 
[77].
Metreleptin for PLD
Use of metreleptin in PLD, whether congenital or acquired, 
is off-label in the United States as of the writing of this 
review. However, data suggest that the drug may be ben-
eficial in a subset of patients with PLD. Metreleptin treat-
ment was associated with normalization of serum leptin 
levels within 3 months and decreased triglycerides but not 
improvement in glycemic control in patients with moder-
ate or severe hypoleptinemia and FPLD (Dunnigan variety) 
[78]. In the NIH study, metabolic parameters improved over 
1 year of treatment with metreleptin in patients with PLD; 
however, the magnitude of reduction in metabolic param-
eters was less than that observed in patients with GLD [2].
Some findings suggest that patients with severe PLD may 
benefit most from leptin replacement therapy. In an analysis 
from the NIH cohort, metreleptin appeared more effective in 
patients with higher (vs. lower) baseline metabolic thresh-
olds (baseline HbA1c > 7.0 or > 8.0%, triglycerides > 300 
or > 500 mg/dL, and leptin < 4 ng/mL) [2]. In a separate 
study, a small subset of patients with severe abnormalities at 
baseline (HbA1c ≥ 8.0% or triglycerides ≥ 500 mg/dL) who 
were treated with metreleptin for 1 year appeared to derive 
substantial benefit from treatment compared with the overall 
treated population [79].
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Efficacy of metreleptin in children with lipodystrophy
There is some evidence that metreleptin is effective in pedi-
atric patients with GLD or PLD. Improvements in glycemic 
parameters, triglycerides, liver histology, and markers of 
liver health were achieved over 1 year of treatment in 53 
patients with GLD or PLD and were maintained throughout 
a mean follow-up of 5 years in the NIH cohort [80]. Metrel-
eptin therapy did not accelerate or trigger puberty, and it was 
associated with normalization of growth trajectory in this 
cohort. However, only 8 patients with PLD were included, 7 
of which were > 12 years old, which limits generalizing this 
finding among younger children with PLD.
Metreleptin tolerability
The most frequent adverse events associated with met-
releptin among patients with GLD (n = 48) receiving 
treatment for a median of 2.7 years were headache (13%), 
hypoglycemia (13%), and decreased weight (13%) [69]. In 
the same study, antimetreleptin antibodies were detected 
in 36 of 43 patients examined, and 2 individuals had neu-
tralizing antibodies, which were associated with infection 
and loss of metabolic control [69]. Risks of neutralizing 
antibodies are unclear and should be weighed alongside 
the benefits of therapy [70].
Lymphoma has been reported in patients with AGL, 
both in the absence and presence of metreleptin treatment 
[81]. The increased risk of malignancy in these individu-
als may be attributable to autoimmune disease; however, 
a role of metreleptin in tumor growth cannot be ruled out 
[81].
Conclusions
Lipodystrophy disorders are a diverse collection of rare 
congenital or acquired disorders of adipose tissue that 
range from mild to severe, result in fat loss and metabolic 
disease, and many are characterized by leptin deficiency. 
Because lipodystrophy is an ultra-rare disease, it is pos-
sible that the practicing clinician will never encounter a 
patient with GLD or PLD; however, the phenotype and 
presentation are sufficiently distinct that such patients can 
be recognized and diagnosed in most instances. Standard 
of care for lipodystrophy includes treatment with leptin 
replacement if indicated, aggressive treatment of comor-
bidities such as diabetes and dyslipidemia, and genetic 
screening of relatives, if warranted.
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